|
|
|
|
NCI at AACR COVID-19 and Cancer
WEDNESDAY, FEBRUARY 3
Thank you for joining NCI as we showcase our research and programs at the American Association for Cancer Research (AACR) Virtual Meeting: COVID-19 and Cancer.
The meeting will take place February 3-5, 2021. The full meeting program is available online, and registration is still available. Content will be posted on-demand shortly after the meeting concludes, and will remain available for 90 days.
|
Forum 5: Workforce Issues
NCI Deputy Director, Dr. Dinah S. Singer, will participate in a forum on workforce issues, moderated by Dr. Liz Jaffee. The panel will also include Dr. Cheryl L. Willman of The University of New Mexico Comprehensive Cancer Center and Dr. Robert A. Winn of VCU Massey Cancer Center.
Join this session on Friday, February 5, 1-2 PM ET
|
|
Forum 1: Cancer Trial Design/Experience During COVID-19
In this session, Director of the NCI Community Oncology Research Program (NCORP), Dr. Worta McCaksill-Stevens, will join other panelists to share insights on how institutions have adapted to patient care during the pandemic. She will also discuss the pandemic's impact on screening modality, moving forward with clinical trials, and screening prioritizations.
Join this session Wednesday, February 3, 1-2 PM ET
|
Symposium 10: Health Inequities and Disparities in the COVID-19 Pandemic
NCI's Dr. Michael Halpern will discuss how the COVID-19 pandemic has led to delays in cancer screening/diagnosis, delays in cancer treatment, and job loss for individuals with cancer. His session will highlight how all of these, and the increased risk of severe illness from COVID-19 infections, can increase the already substantial financial and insurance challenges present among individuals with cancer.
Join this session on Friday, February 5, 10:45 AM-12:35 PM ET
|
Symposium 12: Epidemiology and Registries of COVID-19 and Cancer
In this session, NCI's Mr. Todd Golden will share how COVID-19 has disrupted the delivery of oncology services across the U.S. As part of this discussion, he will highlight how pathology volume trends over the past 3 years quantify this impact on cancer screening and treatment.
Join this session Friday, February 5, 2:15-4:05 PM ET
|
The Human SARS-CoV-2 Serology Standard, a reagent intended to harmonize assays that measure anti-SARS-CoV-2 antibodies, is now available. The standard enables comparisons between different SARS-CoV-2 serology studies, including studies evaluating the immune response to different COVID-19 candidate vaccines.
Developed by researchers at NCI’s Frederick National Laboratory for Cancer Research, the Human SARS-CoV-2 Serology Standard became available to researchers to order in late December 2020.
Researchers may request the Human SARS-CoV-2 Serology Standard by completing the request form available on the FNL website and submitting it to SSNCCbiospecimens@nih.gov.
|
|
